IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Toni CECCARDI et al. Art Unit: 1645

Filed: July 9, 2001

Serial No.: 09/900,448

Atty. Docket: CL001272

Examiner: TBA

For: ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED

PROTEINS, AND USES THEREOF

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: August 12, 2003

Justin D. Karjala, Reg No. 43,704

Celera Genomics

11-

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	09/900,448		
Filing Date	July 9, 2001		
First Named Inventor	Toni CECCARDI et al.		
Art Unit	1645		
Examiner Name	TBA		
Attorney Docket Number	CL001272		

U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					
		US-		ļ			
		US-					
		US-					
i		∪s-					
		US-					
		us-					
		US-					
		US-					
		us-					
		US-	İ				
		us-					
		US-					
j		us-			- *		
		US-					
ĺ		US-					
ĺ		US-					
İ		US-					
.		US-					
İ		US-					

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relavant Figures Appear	Te
		WO 01 54477 A2	8/2/2001	Hyseq Inc.		
		EP 1 033 401 A2	9/6/2000	Genset		
				-		
		*				

Examiner Signature	management part - treatingsides (critic)	w ^a da webesala	to and these type of these of the design of the manifestation	Date Considered	
ल दिशीपर	Section	4-1681		- 1 Va -	
memajor)	ing open-	1, 1,	the state of the s	11 (1111)	

policant is under sitated designation of unperhiptional. He is to be accounted for that is the appropriate of the document of the two policants of the patent documents the indication of the year of the reign of the Emperor must precede the senial number of the patent document. The appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. Washington, Dr. 2023 from Nov. 18 and Robinston to the Amount of the Amount of the Chief Information Officer. U.S. Patent and Trademark Office. Washington, Dr. 2023 from Nov. 18 and Robinston to the Amount of the Amount of the Amount of the Chief Information Officer.

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contains a valid OMB.

ubstitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known				
Application Number	09/900,448			
Filing Date	July 9, 2001			
First Named Inventor	Toni CECCARDI et al.			
Group Art Unit	1645			
Examiner Name	TBA			
Attorney Docket Number	CL001272			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	ē	Takahashi et al. "Complete Amino Acid Sequence of Human Hemopexin, The Heme-Binding Proteins of Serum." Proc. Natl. Acad. Sci. UDS. January 1985, Vol. 82, No. 1, Pages 73-77.		
		International Search report dated May 15, 2003.		
		*		

Jimni Sidnature

onsidéred

^{15.}XAMINER I Initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Transfation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any imments on the amount of time iccurrenced to upon teleform songly resemble to the Chief Intermediate US. In the individual case. Any imments on the amount of time iccurrenced to upon the teleform songly resemble to the Chief Intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of time iccurrence and intermediate US. In the individual case. Any imments on the amount of the individual case. Any imments on the amount of the individual case. Any imments on the amount of the individual case. Any imments on the individual case. Any imments of the individual case. Any imments of the individual case. Any imments on the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any imments of the individual case. Any immen